# Correlia Biosystems

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/correlia-biosystems

- Industry: Biotechnology
- Headquarters: Berkeley, US
- Website: www.correliabio.com
- Total disclosed funding: $9.6M
- Latest round: Series A (Oct 2, 2020)
- Investors on record: 4

## About

Correlia Biosystems, Inc. develops innovative biotechnology solutions, focusing on advanced diagnostic tools and therapeutic platforms aimed at enhancing clinical decision-making in the life sciences sector.Founded in 2013 in Berkeley, US, Correlia Biosystems, Inc. specializes in biotechnology solutions, focusing on diagnostics and therapeutics. The company was established by Akwasi Apori and Kursad Araz. In May 2023, Correlia raised USD 1.25 mn in a Series A funding round, achieving a total amount raised of USD 1.25 mn and a current valuation of USD 1.861 mn. The company has completed 3 deals, with the most recent one occurring in May 2023.Correlia specializes in developing biotechnology solutions to meet critical needs in the life sciences sector. Their core offerings consist of advanced diagnostic tools and therapeutic platforms that utilize proprietary technologies for genetic analysis and disease management. These products are designed to improve the accuracy and efficiency of clinical diagnostics, serving hospitals, laboratories, and research institutions primarily in North America, Europe, and parts of Asia.Correlia generates revenue through direct sales of its diagnostic and therapeutic products to healthcare providers and research institutions. The company operates a business-to-business model, partnering with hospitals and laboratories for product distribution. Transactions typically involve one-time purchases or recurring orders, ensuring a consistent revenue stream supported by strong demand for its offerings in the healthcare market.Correlia plans to utilize the USD 1.25 mn from its Series A funding, raised in May 2023, to support the development of new products and expand its market presence. The company is focusing on launching new diagnostic tools and therapeutic platforms within the next year while targeting expansion into European and Asian markets by 2025.

## Funding rounds

- Series A, Oct 2, 2020, $9.6M — Regents of the University of California, Cota Capital, NeoTribe Ventures
- Seed, Jul 1, 2018 — Blue Bear Ventures

## Investors

- Blue Bear Ventures (https://capitalatlas.ai/funds/blue-bear-ventures) — Seed
- Regents of the University of California — Series A
- Cota Capital (https://capitalatlas.ai/funds/cota-capital) — Series A
- NeoTribe Ventures (https://capitalatlas.ai/funds/neotribe-ventures) — Series A